NYSE:ENOV - New York Stock Exchange, Inc. - US1940141062 - Common Stock - Currency: USD
42.71
-1.19 (-2.71%)
The current stock price of ENOV is 42.71 USD. In the past month the price decreased by -9.65%. In the past year, price decreased by -32.04%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
SYK | STRYKER CORP | 31.4 | 145.92B | ||
MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
DXCM | DEXCOM INC | 53.81 | 34.68B | ||
RMD | RESMED INC | 26.21 | 34.03B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Enovis Corp. operates as a medical technology growth company. The company is headquartered in Wilmington, Delaware and currently employs 6,550 full-time employees. The company went IPO on 2008-05-08. The company is focused on developing clinically differentiated solutions by manufacturing and distributing medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. The company operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment develops, manufactures, and distributes rigid bracing products, orthopedic soft goods, vascular systems and compression garments, and hot and cold therapy products and offers recovery sciences products in the clinical rehabilitation and sports medicine markets, such as bone growth stimulators and electrical stimulators used for pain management. The Reconstructive segment develops, manufactures, and markets a variety of knee, hip, shoulder, elbow, foot, ankle, and finger implant products and surgical productivity tools. The company also provides Novastep, a minimally invasive surgery (MIS) foot and ankle solutions.
ENOVIS CORP
2711 Centerville Road, Suite 400
Wilmington DELAWARE US
Employees: 6550
Company Website: https://www.enovis.com/
Investor Relations: https://ir.enovis.com/
Phone: 13022529160
The current stock price of ENOV is 42.71 USD. The price decreased by -2.71% in the last trading session.
The exchange symbol of ENOVIS CORP is ENOV and it is listed on the New York Stock Exchange, Inc. exchange.
ENOV stock is listed on the New York Stock Exchange, Inc. exchange.
17 analysts have analysed ENOV and the average price target is 66.3 USD. This implies a price increase of 55.23% is expected in the next year compared to the current price of 42.71. Check the ENOVIS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ENOVIS CORP (ENOV) has a market capitalization of 2.43B USD. This makes ENOV a Mid Cap stock.
ENOVIS CORP (ENOV) currently has 6550 employees.
ENOVIS CORP (ENOV) has a support level at 38.71 and a resistance level at 44.83. Check the full technical report for a detailed analysis of ENOV support and resistance levels.
The Revenue of ENOVIS CORP (ENOV) is expected to grow by 23.86% in the next year. Check the estimates tab for more information on the ENOV EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ENOV does not pay a dividend.
ENOVIS CORP (ENOV) will report earnings on 2025-02-26, after the market close.
The PE ratio for ENOVIS CORP (ENOV) is 16.18. This is based on the reported non-GAAP earnings per share of 2.64 and the current share price of 42.71 USD. Check the full fundamental report for a full analysis of the valuation metrics for ENOV.
The outstanding short interest for ENOVIS CORP (ENOV) is 8.88% of its float. Check the ownership tab for more information on the ENOV short interest.
ChartMill assigns a fundamental rating of 4 / 10 to ENOV. While ENOV is still in line with the averages on profitability rating, there are concerns on its financial health.
Over the last trailing twelve months ENOV reported a non-GAAP Earnings per Share(EPS) of 2.64. The EPS increased by 13.3% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -2.15% | ||
ROE | -3.58% | ||
Debt/Equity | 0.4 |
ChartMill assigns a Buy % Consensus number of 84% to ENOV. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of 18.15% and a revenue growth 23.86% for ENOV